Revicki DA, Wood M, Maton PN, et al. 1998. The impact of gastro- esophageal reﬂux disease on health-related quality of life. Am J Med, 104:252–8. Richter JE, Kahrilas PJ, Johanson J, et al. 2001. Efﬁcacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol, 96:656–65. Rohss K, Hasselgren G, Hedenstrom H. 2002. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reﬂux disease. Dig Dis Sci, 47:954–8. Rohss K, Lind T, Wilder-Smith C. 2004. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omepra- zole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reﬂux symptoms. Eur J Clin Pharmacol, 60:531–9. Schmitt C, Lightdale CJ, Hwang C, et al. 2006. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esome- prazole 40 mg. and omeprazole 20 mg. for the treatment of erosive esophagitis. Dig Dis Sci, 51:844–50. Scholten T, Gatz G, Hole U. 2003. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efﬁcacy in relieving GERD-related symptoms. Aliment Pharmacol Ther, 18:587–94. Simon B, Muller P, Pascu O, et al. 2003. Intra-oesophageal pH proﬁles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reﬂux disease. Eur J Gastroenterol Hepatol, 15:791–9. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. 2001. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reﬂux disease: a controlled trial of on-demand therapy for 6 months. Aliment Pharmacol Ther, 15:347–54. Talley NJ, Venables TL, Green JR, et al. 2002. Esomeprazole 40 mg and 20 mg is efﬁcacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reﬂux disease: a placebo- controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol, 14:857–63. Esomeprazole in GERD Tsai HH, Chapman R, Shepherd A, et al. 2004. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lanso- prazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reﬂux patients: the COMMAND Study. Aliment Pharmacol Ther, 20:657–65. Vakil N, Fennerty MB. 2003. Direct comparative trials of the efﬁcacy of proton pump inhibitors in the management of gastro-oesophageal reﬂux disease and peptic ulcer disease. Aliment Pharmacol Ther, 18:559–68. Vakil NB, Shaker R, Johnson DA, et al. 2001. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efﬁcacy and safety. Aliment Pharmacol Ther, 15:927–35. Vakil N, van Zanten SV, Kahrilas P, et al. 2006. The Montreal deﬁnition and classiﬁcation of gastroesophageal reﬂux disease: a global evidence- based consensus. Am J Gastroenterol, 101:1900–20; quiz 1943. Verdu EF, Armstrong D, Fraser R, et al. 1995. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut, 36:539–43. Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. 2003. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion, 68:184–8. Wu JC, Chan FK, Ching JY, et al. 2004. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reﬂux disease: a double blind, placebo controlled, randomised trial. Gut, 53:174–9. Therapeutics and Clinical Risk Management 2007:3(4) 663